RAPAMUNE
Drug
PFIZER INC.
Total Payments
$4.3M
Transactions
59
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $739,030 | 6 | 0 |
| 2022 | $158,647 | 1 | 0 |
| 2021 | $143,025 | 5 | 3 |
| 2020 | $498,152 | 9 | 0 |
| 2019 | $1.3M | 7 | 0 |
| 2018 | $1.2M | 18 | 1 |
| 2017 | $311,910 | 13 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.3M | 55 | 100.0% |
| Food and Beverage | $99.92 | 4 | 0.0% |
Payments by Type
Research
$4.3M
55 transactions
General
$99.92
4 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A FUTILITY TRIAL OF SIROLIMUS IN MULTIPLE SYSTEM ATROPHY | PFIZER INC. | $1.7M | 0 |
| MULTICENTER INTERVENTIONAL LYMPHANGIOLEIOMYOMATOSIS EARLY DISEASE MILED TRIAL A PHASE 3 STUDY OF SIROLIMUS FOR LYMPHANGIOLEIOMYOMATOSIS | PFIZER INC. | $1.3M | 0 |
| A PHASE II SINGLEARM OPENLABEL MULTICENTER STUDY OF SIROLIMUS IN PREVIOUSLY TREATED IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE | PFIZER INC. | $446,856 | 0 |
| SIROLIMUS FOR COWDEN SYNDROME WITH COLON POLYPOSIS | PFIZER INC. | $337,181 | 0 |
| A POPULATION BASED COHORT STUDY TO MONITOR THE SAFETY AND EFFECTIVENESS OF SIROLIMUS IN PATIENTS WITH SPORADIC LYMPHANGIOLEIOMYOMATOSIS SLAM | PFIZER INC. | $259,650 | 0 |
| PILOT CLINICAL DRUG TRIAL OF SIROLIMUS FOR COGNITIVE IMPAIRMENTS IN STURGEWEBER SYNDROME | PFIZER INC. | $135,080 | 0 |
| SIROLIMUS TREATMENT IN HOSPITALIZED PATIENTS WITH COVID19 PNEUMONIA | PFIZER INC. | $77,885 | 0 |
| VINCRISTINE VS SIROLIMUS TO TREAT HIGH RISK KAPOSIFORM HEMANGIOENDOTHELIOMA | PFIZER INC. | $60,791 | 0 |
| A PILOT STUDY EVALUATING THE USE OF THE MTOR INHIBITOR SIROLIMUS IN CHILDREN AND YOUNG ADULTS WITH DESMOIDTYPE FIBROMATOSIS | PFIZER INC. | $16,185 | 0 |
Top Doctors Receiving Payments for RAPAMUNE
Ad
Manufacturing Companies
- PFIZER INC. $4.3M
Product Information
- Type Drug
- Total Payments $4.3M
- Total Doctors 4
- Transactions 59
About RAPAMUNE
RAPAMUNE is a drug associated with $4.3M in payments to 4 healthcare providers, recorded across 59 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2017 to 2023. In 2023, $739,030 was paid across 6 transactions to 0 doctors.
The most common payment nature for RAPAMUNE is "Unspecified" ($4.3M, 100.0% of total).
RAPAMUNE is associated with 9 research studies, including "A FUTILITY TRIAL OF SIROLIMUS IN MULTIPLE SYSTEM ATROPHY" ($1.7M).